HERON THERAPEUTICS, INC. /DE/ (HRTX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$26.1M
Cash & Equivalents
$1.5M
Quarterly Burn Rate
51 mo
Est. Cash Runway
$78M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-31 | Phase2 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06952868 | Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers | PHASE2 | Recruiting | 24 |
| NCT07003139 | A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors | PHASE2 | Recruiting | 10 |
| NCT07691775 | A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors | PHASE2 | Recruiting | 30 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-02 | 8-K | HERON THERAPEUTICS, INC. /DE/ (HRTX) (CIK 0000818033) - 8-K | EDGAR |